Last updated: 9 June 2026

Supplied strictly for in vitro laboratory research. Not for human consumption.

CJC-1295 and Ipamorelin are two growth-hormone-axis peptides that are most often studied together — and the pairing is one of the most researched growth hormone secretagogue combinations in peptide science. The reason is mechanistic: each acts on a different receptor, and together they stimulate the body’s own growth hormone release more than either does alone. This guide explains what each peptide is, why they are combined, and what the research shows, for research context only.

What is CJC-1295?

CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH), derived from the GRF(1-29) sequence with modifications that improve its stability. It binds the GHRH receptor on pituitary somatotroph cells, raising intracellular cAMP and stimulating the synthesis and pulsatile release of growth hormone.

It exists in two forms that differ mainly in duration:

With DAC (Drug Affinity Complex) — binds to albumin in the bloodstream, giving a long half-life of roughly 6–8 days and sustained activity. In a published clinical study (Walker et al., 2006), CJC-1295 with DAC produced dose-dependent increases in GH and IGF-1 lasting several days from a single dose.
Without DAC (also called Mod GRF 1-29) — a short-acting form with a half-life of around 30 minutes, closer to the body’s natural pulse timing.

CJC-1295 was originally developed by ConjuChem as a clinical drug candidate; early-phase trials characterised its pharmacology well, but development was discontinued for commercial reasons, and it is not an approved medicine.

What is Ipamorelin?

Ipamorelin is a selective growth hormone secretagogue — a pentapeptide that acts as an agonist at the ghrelin receptor (GHS-R1a), the same receptor through which the hormone ghrelin triggers growth hormone release. Developed in the late 1990s, Ipamorelin is noted in the research literature for its selectivity: compared with earlier growth-hormone-releasing peptides (GHRPs), it stimulates GH release with little meaningful effect on cortisol or prolactin.

Why they are studied together

The combination works because the two peptides engage two genuinely independent receptor systems on the same pituitary cells:

CJC-1295 acts on the GHRH receptor through a cAMP-dependent pathway.
Ipamorelin acts on the ghrelin receptor (GHS-R1a) through a distinct, calcium-dependent pathway.

Because the pathways are separate, stimulating both at once produces a synergistic — supra-additive — growth hormone response, larger than the sum of either compound alone. Research demonstrating this dual-receptor synergy dates back to work published in 1999. A common analogy in the literature: GHRH signalling acts like an accelerator while the ghrelin pathway releases the brake, so engaging both approximates the body’s natural dual-signal control of GH release more closely than a single agent.

Part of the GH-axis family

CJC-1295 and Ipamorelin sit alongside tesamorelin within the growth-hormone-axis peptides. Tesamorelin, also a GHRH analog, is short-acting and the only one of this family with full FDA approval (for a specific indication); CJC-1295 with DAC, by contrast, is designed for sustained activity. Comparing their durations and receptor targets is a useful way to understand how this class is studied.

The state of the evidence

The pharmacology of both compounds is reasonably well characterised, and the synergy of the combination is well documented at the mechanistic level. That said, human clinical research on the pairing remains limited in scale compared with approved medicines, and neither CJC-1295 nor Ipamorelin is approved for human use. Both are appropriately treated as research compounds.

Research and sourcing considerations

As with any research peptide, reproducible results depend on verified identity and purity. A research-grade CJC-1295 / Ipamorelin blend should be supplied with independent HPLC purity testing (≥99% purity) and a batch-specific certificate of analysis (COA) for the specific vial supplied.

DXB Peptides supplies the research-grade CJC-1295 / Ipamorelin blend for in vitro laboratory use — HPLC-tested to ≥99% purity with a batch-specific COA, cold-chain handled and delivered across the UAE.

Frequently asked questions

What is the difference between CJC-1295 and Ipamorelin? CJC-1295 is a GHRH analog acting on the GHRH receptor; Ipamorelin is a selective ghrelin-receptor agonist. They engage different pathways that both lead to GH release.

Why are they combined? Because their receptor pathways are independent, activating both simultaneously produces a synergistic GH response greater than either alone.

What is the difference between CJC-1295 with and without DAC? The DAC form binds albumin for a long (~6–8 day) half-life; the no-DAC form (Mod GRF 1-29) is short-acting (~30 minutes).

Are CJC-1295 and Ipamorelin approved? No. Neither is approved for human use; both are research compounds.

Important note

This CJC-1295 / Ipamorelin blend is supplied strictly for in vitro laboratory research. It is not a medicine, is not approved for human use, and is not for human consumption or in vivo administration.

Explore the full catalogue: Research peptides UAE

What Is CJC-1295 & Ipamorelin? GHRH + GHRP Stack